IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
14/09/26	€0.1230	-40.00%
11/09/26	€0.2050	-5.96%
10/09/26	€0.2180	-0.46%
09/09/26	€0.2190	-3.10%
08/09/26	€0.2260	+27.32%

Delayed Quote Börse Stuttgart

More quotes

Delayed Börse Stuttgart 22:18:00 14/09/2026 +03			5-day change	1st Jan Change
0.1230 ^EUR	-40.00%		-30.70%	+53.75%

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT

Market Cap	881K 1.02M 831K 754K 1.41M 97.4M 1.42M 9.92M 3.82M 49.41M 3.82M 3.73M 157M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.57M -2.1M -1.91M -3.58M -246M -3.6M -25.12M -9.68M -125M -9.66M -9.45M -398M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Markets		Quality
Euronext Paris	ALINT	Real-time
Börse Stuttgart	7N8	Delayed

09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
06-16	IntegraGen Enters Receivership Proceedings
05-28	IntegraGen to file for court-ordered receivership
04-24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
04-23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/10/25	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/07/25	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
02/07/25	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
29/04/25	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/01/25	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
18/10/24	IntegraGen: losses reduced, share price soars
30/07/24	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI

IntegraGen Stock Börse Stuttgart

Stocks

7N8

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news: IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Price Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
02/07/25	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
29/04/25	IntegraGen: 2024 Annual Results	BU
15/01/25	IntegraGen : Inside Information / Information on annual revenues	PU
15/01/25	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

10:02am	Bourse : Capgemini vend sa division CGS, Euronext reparle consolidation et J&J pourrait céder son orthopédie
08:37am	La love story du marché avec l'IA connaît quelques ratés
08:10am	Deux offres de reprise déposées pour IntegraGen
09-11	IntegraGen annonce le dépôt de deux offres de reprise dans le cadre de son redressement judiciaire
06-16	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime

1 day	-40.00%
1 week	-30.70%
Current month	-29.91%
1 month	-32.23%
3 months	-38.35%
6 months	-28.70%
Current year	+53.75%

1 week	0.12	0.23
1 month	0.12	0.23
Current year	0.1	0.33
1 year	0.07	0.33
3 years	0.07	1.32
5 years	0.07	1.46
10 years	0.07	1.46

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	09/11/2009
Virginie de Coster DFI	Director of Finance/CFO	-	01/01/2023
Berengere Genin COO	Chief Operating Officer	-	01/01/2024

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	22/09/2011
Jean-Pol Detiffe BRD	Director/Board Member	53	01/01/2021
François Blondel BRD	Director/Board Member	63	31/12/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	-40.00%	-30.70%	-	-	1.53M
IOVANCE BIOTHERAPEUTICS, INC.	+6.98%	+5.46%	+304.19%	+97.52%	3.9B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+2.67%	+1.60%	+89.07%	+298.23%	3.86B
VERACYTE, INC.	+0.82%	-3.29%	+28.82%	+62.85%	3.29B
CAREDX, INC.	+4.30%	+4.34%	+274.43%	+540.18%	2.6B
BGI GENOMICS CO., LTD.	+2.37%	-0.38%	-33.13%	-30.48%	2.05B
FREENOME, INC.	+3.41%	-11.89%	+36.21%	-	1.54B
SEEGENE, INC.	+1.27%	+0.16%	+22.88%	+42.00%	1.07B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+3.14%	-5.77%	+149.08%	-34.41%	973M
CURIOX BIOSYSTEMS CO., LTD	-0.83%	-0.10%	-6.48%	+78.95%	616M
Average	-1.63%	-3.48%	+96.12%	+131.86%	2.21B
Weighted average by Cap.	+3.22%	-2.85%	+125.15%	+171.07%

	2019	2020
Net sales	8.28M 9.56M 7.81M 7.09M 13.3M 916M 13.39M 93.32M 35.96M 465M 35.89M 35.1M 1.48B	9M 10.39M 8.49M 7.71M 14.45M 996M 14.56M 101M 39.09M 505M 39.01M 38.15M 1.61B
Net income	-285K -329K -269K -244K -457K -31.51M -461K -3.21M -1.24M -15.98M -1.23M -1.21M -50.81M	-375K -433K -354K -321K -602K -41.48M -607K -4.23M -1.63M -21.04M -1.63M -1.59M -66.9M
Net Debt	-2.52M -2.91M -2.38M -2.16M -4.04M -279M -4.07M -28.39M -10.94M -141M -10.92M -10.68M -449M	-3.11M -3.59M -2.93M -2.66M -4.99M -344M -5.03M -35.04M -13.5M -174M -13.48M -13.18M -555M